MX2023014405A - Terapia combinada que comprende un inhibidor de mat2a y un inhibidor de prmt de tipo ii. - Google Patents
Terapia combinada que comprende un inhibidor de mat2a y un inhibidor de prmt de tipo ii.Info
- Publication number
- MX2023014405A MX2023014405A MX2023014405A MX2023014405A MX2023014405A MX 2023014405 A MX2023014405 A MX 2023014405A MX 2023014405 A MX2023014405 A MX 2023014405A MX 2023014405 A MX2023014405 A MX 2023014405A MX 2023014405 A MX2023014405 A MX 2023014405A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- type
- mat2a
- prmt
- combined therapy
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- ZTNQNZDNHUAVEI-UHFFFAOYSA-N CC=1SC2=C(N=1)C=CC(=C2)C1=C(NC=2N(C1=O)N=C(C=2C1=CC=CC=C1)C1=CC=CC=C1)NC1=NC=CC=C1 Chemical compound CC=1SC2=C(N=1)C=CC(=C2)C1=C(NC=2N(C1=O)N=C(C=2C1=CC=CC=C1)C1=CC=CC=C1)NC1=NC=CC=C1 ZTNQNZDNHUAVEI-UHFFFAOYSA-N 0.000 title 1
- 229940125535 MAT2A inhibitor Drugs 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 102100035947 S-adenosylmethionine synthase isoform type-2 Human genes 0.000 abstract 3
- 239000013066 combination product Substances 0.000 abstract 3
- 229940127555 combination product Drugs 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108020000912 Protein arginine N-methyltransferase Proteins 0.000 abstract 1
- 102000003708 Protein arginine N-methyltransferase Human genes 0.000 abstract 1
- 101710167557 S-adenosylmethionine synthase isoform type-2 Proteins 0.000 abstract 1
- 101000985737 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Protein arginine N-methyltransferase HSL7 Proteins 0.000 abstract 1
- 101000651946 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein arginine N-methyltransferase skb1 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196008P | 2021-06-02 | 2021-06-02 | |
| US202263362438P | 2022-04-04 | 2022-04-04 | |
| US202263364360P | 2022-05-09 | 2022-05-09 | |
| PCT/US2022/072693 WO2022256806A1 (en) | 2021-06-02 | 2022-06-01 | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014405A true MX2023014405A (es) | 2024-04-30 |
Family
ID=84323602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014405A MX2023014405A (es) | 2021-06-02 | 2022-06-01 | Terapia combinada que comprende un inhibidor de mat2a y un inhibidor de prmt de tipo ii. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240108626A1 (enExample) |
| EP (1) | EP4347569A4 (enExample) |
| JP (1) | JP2024521920A (enExample) |
| KR (1) | KR20240019172A (enExample) |
| AU (1) | AU2022287057A1 (enExample) |
| BR (1) | BR112023025360A2 (enExample) |
| CA (1) | CA3220160A1 (enExample) |
| CL (1) | CL2023003603A1 (enExample) |
| IL (1) | IL308853A (enExample) |
| MX (1) | MX2023014405A (enExample) |
| WO (1) | WO2022256806A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| US12503467B2 (en) | 2018-12-10 | 2025-12-23 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CN116568677B (zh) | 2020-07-31 | 2026-07-28 | 探戈医药股份有限公司 | 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物 |
| IL308853A (en) * | 2021-06-02 | 2024-01-01 | Ideaya Biosciences Inc | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
| EP4458812A1 (en) * | 2021-12-27 | 2024-11-06 | Medshine Discovery Inc. | Pyrazole-1(2h)-phthalazinone compound and application thereof |
| EP4469447A1 (en) * | 2022-01-26 | 2024-12-04 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CN118946549A (zh) * | 2022-04-22 | 2024-11-12 | 北京望实智慧科技有限公司 | 稠和哒嗪酮化合物作为prmt5抑制剂 |
| WO2023246873A1 (zh) * | 2022-06-23 | 2023-12-28 | 南京明德新药研发有限公司 | 氨基取代的杂芳基衍生物及其应用 |
| US20250376473A1 (en) * | 2022-07-01 | 2025-12-11 | Cytosinlab Therapeutics Co., Ltd. | Prmts inhibitor and use thereof |
| WO2024027703A1 (zh) * | 2022-08-02 | 2024-02-08 | 上海艾力斯医药科技股份有限公司 | 一种prmt5抑制剂、其制备方法及应用 |
| KR20250108633A (ko) * | 2022-10-25 | 2025-07-15 | 탱고 테라퓨틱스, 인크. | 결정질 형태, 약제학적 조성물 및 이의 사용 방법 |
| CN120265615A (zh) * | 2022-11-29 | 2025-07-04 | 正大天晴药业集团股份有限公司 | 含有二氢酞嗪的化合物 |
| WO2024118943A2 (en) * | 2022-11-30 | 2024-06-06 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor |
| TW202440126A (zh) * | 2022-11-30 | 2024-10-16 | 美商安進公司 | 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療 |
| WO2024140923A1 (zh) * | 2022-12-30 | 2024-07-04 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
| CN118359607A (zh) * | 2023-01-17 | 2024-07-19 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
| AU2024252435A1 (en) * | 2023-04-13 | 2025-10-16 | Glaxosmithkline Intellectual Property (No.4) Limited | Combination therapy comprising a mat2a inhibitor and a topoisomerase inhibitor, a splicing inhibitor sulfonamide, or a kif18 inhibitor |
| JP2026515196A (ja) * | 2023-04-28 | 2026-05-14 | ファーマエンジン インコーポレーテッド | Ｍｔａ協同的ｐｒｍｔ５阻害剤 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN116283800B (zh) * | 2023-05-16 | 2023-07-18 | 英矽智能科技(上海)有限公司 | 氧代喹唑啉类化合物及其应用 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| IL326348A (en) * | 2023-08-08 | 2026-04-01 | Mirati Therapeutics Inc | Methods and compositions for treating malignant peripheral nerve sheath tumors |
| IL327063A (en) * | 2023-09-15 | 2026-05-01 | Ideaya Biosciences Inc | Methods for treating MAT2A-related diseases |
| CN121866246A (zh) * | 2023-09-20 | 2026-04-14 | 西藏海思科制药有限公司 | 一种含氰基的杂环化合物及其用途 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN121889382A (zh) * | 2023-11-08 | 2026-04-17 | 北京泰德制药股份有限公司 | Prmt5抑制剂及其制备方法 |
| CN122341615A (zh) * | 2023-12-01 | 2026-07-03 | 上海翰森生物医药科技有限公司 | 三并环类衍生物抑制剂、其制备方法和应用 |
| AU2025212321A1 (en) | 2024-01-26 | 2026-08-06 | Apeiron Therapeutics (Hong Kong) Ltd. | Pharmaceutical composition containing prmt5 inhibitor and mat2a inhibitor |
| WO2025166308A1 (en) * | 2024-01-31 | 2025-08-07 | Tango Therapeutics, Inc. | Crystalline forms, pharmaceutical compositions and methods of use thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217297A1 (en) * | 2024-04-09 | 2025-10-16 | Tango Therapeutics, Inc. | Prmt5 inhibitors for use in methods of treating mta-accumulating cancer |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025250569A1 (en) * | 2024-05-29 | 2025-12-04 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017096165A1 (en) * | 2015-12-03 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Mat2a inhibitors for treating mtap null cancer |
| US12503467B2 (en) * | 2018-12-10 | 2025-12-23 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors |
| CN120208880A (zh) * | 2019-09-12 | 2025-06-27 | 米拉蒂医疗股份有限公司 | Mta-协同prmt5抑制剂 |
| GEP20247638B (en) * | 2019-10-22 | 2024-07-10 | Lupin Ltd | Pharmaceutical combination of prmt5 inhibitors |
| US12403137B2 (en) * | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| IL308853A (en) * | 2021-06-02 | 2024-01-01 | Ideaya Biosciences Inc | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
-
2022
- 2022-06-01 IL IL308853A patent/IL308853A/en unknown
- 2022-06-01 AU AU2022287057A patent/AU2022287057A1/en active Pending
- 2022-06-01 JP JP2023574589A patent/JP2024521920A/ja active Pending
- 2022-06-01 WO PCT/US2022/072693 patent/WO2022256806A1/en not_active Ceased
- 2022-06-01 BR BR112023025360A patent/BR112023025360A2/pt unknown
- 2022-06-01 CA CA3220160A patent/CA3220160A1/en active Pending
- 2022-06-01 MX MX2023014405A patent/MX2023014405A/es unknown
- 2022-06-01 EP EP22817027.0A patent/EP4347569A4/en active Pending
- 2022-06-01 KR KR1020237045309A patent/KR20240019172A/ko active Pending
-
2023
- 2023-11-03 US US18/501,729 patent/US20240108626A1/en active Pending
- 2023-12-01 CL CL2023003603A patent/CL2023003603A1/es unknown
-
2024
- 2024-01-05 US US18/405,638 patent/US12115163B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4347569A4 (en) | 2025-03-26 |
| CL2023003603A1 (es) | 2024-07-12 |
| IL308853A (en) | 2024-01-01 |
| US20240108626A1 (en) | 2024-04-04 |
| CA3220160A1 (en) | 2022-12-08 |
| BR112023025360A2 (pt) | 2024-02-20 |
| AU2022287057A1 (en) | 2023-12-14 |
| US20240173326A1 (en) | 2024-05-30 |
| WO2022256806A1 (en) | 2022-12-08 |
| US12115163B2 (en) | 2024-10-15 |
| KR20240019172A (ko) | 2024-02-14 |
| JP2024521920A (ja) | 2024-06-04 |
| EP4347569A1 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003603A1 (es) | Terapia de combinación de un inhibidor de mat2a y uno de prmt tipo ii | |
| CO2021009882A2 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer | |
| CO2021009879A2 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer | |
| CO2021017981A2 (es) | Inhibidores heterobicíclicos de mat2a y métodos de uso para el tratamiento del cáncer | |
| BRPI0207961B8 (pt) | uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
| ATE408601T1 (de) | Fredericamycin-derivate | |
| CL2023003965A1 (es) | Inhibidores cdk2. | |
| ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
| MX2024014861A (es) | Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo | |
| BRPI0416981A (pt) | compostos para tratamento de doenças proliferativas de célula | |
| NO20071585L (no) | Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte | |
| ECSP045430A (es) | Terapia de combinación para el tratamiento de cancer | |
| MX2020009773A (es) | Terapia de combinacion. | |
| BR112022026094A2 (pt) | Usos de um inibidor de hif-2a e lenvatinibe, ou um sal farmaceuticamente aceitável do mesmo, e de uma combinação terapêutica, e, kit | |
| CL2025001869A1 (es) | Uso de diferentes compuestos inhibidores de quinasas para tratar cáncer. | |
| BR112022008497A2 (pt) | Derivados terapêuticos da interleucina-22 | |
| CO2025009288A2 (es) | Productos terapéuticos dirigidos al receptor de somatostatina subtipo 2 (sst2r) y usos de la misma | |
| CL2025002366A1 (es) | Compuesto que contiene trifluorometilsulfonilo. | |
| BR112022010702A2 (pt) | Macrociclos para uso no tratamento de doenças | |
| MX2025014866A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos | |
| BR112022012081A2 (pt) | Método para tratar câncer, kit, e, uso de uma combinação terapêutica | |
| EA202190360A1 (ru) | Комбинированная терапия | |
| ATE431742T1 (de) | Modifizierte zytokine für krebs therapie | |
| MX2025009435A (es) | Inhibidor de prmt5 para uso en la terapia contra el cancer | |
| MX2025000539A (es) | Nuevos inhibidores de la localizacion nuclear de la histona metiltransferasa |